EnglishFrenchGermanItalianSpanish

WELCOME TO THE NEWSROOM

WATCH OUR LATEST VIDEO

In the news

Find our most recent press releases and other media below. CONTACT US if you need more details, would like to set up an interview or are a media person on deadline.

– Completes menu for key blood born viral tests – June 15, 2020 (Ann Arbor, MI) – NeuMoDx Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today CE Mark approval for its PCR Human Immunodeficiency Virus (HIV) viral load test. This key test completes the NeuMoDx blood born viral menu which...

– New Software provides capability to perform approximately 400 extractions per 8-hour shift – June 8, 2020 (Ann Arbor, Michigan) NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on central laboratory customers, announced today the release of new software that introduces ‘Extraction Only’ capabilities among other enhancements. The Extraction Only feature provides users the option...

– High throughput system with results in as little as 80 minutes – May 8, 2020 (Ann Arbor, Michigan) NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing high throughput testing solutions to hospital and commercial reference laboratories, announced plans to enhance its U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for...

– STAT results in as little as 80 minutes – May 4, 2020 (Ann Arbor, Michigan) NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing high throughput testing solutions to hospital and commercial reference laboratories, announced it has secured the regulatory CE Mark approval for its NeuMoDx™ SARS-CoV-2 Assay implemented on the NeuMoDx™ Molecular...












































































Coronavirus Assay Information

NeuMoDx™ Molecular, a sample-to-result molecular diagnostic company focused on providing testing solutions to hospital and commercial reference laboratories, has developed a SARS-CoV-2 Assay for use on the high throughput, fully automated NeuMoDx™ 288 and 96 Molecular Systems. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the NeuMoDx™ SARS-CoV-2 Assay implemented on the NeuMoDx™ Molecular Systems.

To learn more about SARS-CoV-2 testing, click here.
To order, click here.